| Patient | Marilyn Monroe |
|---|---|
| Date of birth | 1926-06-01 |
| Identifiers | MRN HR-ML002-SYN-TD; SSN (made up) 000-02-4471 |
| Document date | 1956-06-24 |
| Author | Joanna Whitlock, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Transvaginal ultrasound result and gynecology consultation the same day. [S]
Ms. Monroe returns nine days after her first visit, on the morning of her transvaginal ultrasound, and is seen the same day by Dr. Okoye of gynecology. She started the continuous combined pill and naproxen after the first visit and has had no bleeding yet; she had one day of nausea on the pill, which passed. She has not taken diphenhydramine and has slept a little better with the sleep routine. Her gonorrhea and chlamydia tests and urinalysis from the first visit were negative. She has had her first session with the behavioral health clinician. She asks whether she will need an operation, and whether this will stop her from having children. She has had no thoughts of suicide or self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | Continuous combined pill and naproxen for nine days; no bleeding |
| Pain | Pelvic ache on most days, less than before |
| First-visit tests | Gonorrhea, chlamydia and urinalysis negative |
| Sleep | No diphenhydramine; a little better |
| Her questions | Surgery, and whether she can have children |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | One day of nausea on starting the pill; no bowel pain this week |
| Genitourinary | Positive | Low pelvic ache on most days; no bleeding or urinary symptoms |
| Neurological | Negative | No headaches or visual aura |
| Psychiatric | Positive | Still low but hopeful about the plan; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen 500 mg oral tablet, one tablet by mouth twice daily with food, from two days before an expected bleed until the third day, and for pain flares; no more than 10 days a month | One tablet by mouth twice daily with food when needed for pelvic pain | Oral route | 1956-06-15 | active | S |
| Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg oral tablet, one tablet by mouth daily, taken continuously without a pill-free week | One tablet by mouth daily, continuously | Oral route | 1956-06-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1956-06-24 | Body height | 166 | cm | S |
| 1956-06-24 | Body weight | 56.2 | kg | S |
| 1956-06-24 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 1956-06-24 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1956-06-24 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1956-06-24 | Heart rate | 74 | /min | S |
| 1956-06-24 | Respiratory rate | 14 | /min | S |
| 1956-06-24 | Body temperature | 36.6 | Cel | S |
| 1956-06-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1956-06-24 | Mullerian inhibiting substance [Mass/volume] in Serum or Plasma | 2.6 | ng/mL | Typical range at ages 30 to 34; a low value suggests a smaller ovarian reserve but does not predict natural fertility | Normal | S |
Vital signs recorded on 1956-06-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 110/70, pulse 74; weight 56.2 kg |
| Abdomen | Soft; mild left lower quadrant tenderness; no mass |
| Pelvic | Examined by Dr. Okoye: tender, slightly fixed retroverted uterus; fullness and tenderness in the left adnexa; thickened, tender left uterosacral ligament; no nodule felt in the rectovaginal septum |
| Psychiatric | Anxious about fertility; organized; tearful briefly; no psychotic features |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe painful periods since her teens, worse over the past three years, with pelvic pain between periods, deep pain with intercourse, and painful bowel movements during periods; she misses work for two or three days each cycle. Tender, slightly fixed retroverted uterus with tenderness and fullness in the left adnexa and along the left uterosacral ligament. Suspected endometriosis; transvaginal ultrasound and gynecology consultation booked | resolved | confirmed | N94.6 | S — Synthetic presenting problem linked to her documented endometriosis; superseded by the diagnosis at the consultation. |
| Endometriosis: a 3.4 cm left ovarian endometrioma on transvaginal ultrasound, with a tender, thickened left uterosacral ligament and no deep nodule of the bowel or bladder seen; diagnosed from imaging and examination without surgery, as the ESHRE guideline allows. Synthetic modern episode linked to her documented endometriosis | active | confirmed | N80.102 | S — Synthetic modern diagnosis made at the gynecology consultation; depth is unspecified because no surgery was done. |
| Major depressive disorder, single episode, moderate: about two months of low mood, poor sleep on painful nights, low energy, guilt about missed work, and poor concentration (PHQ-9 12, item 9 scored 0; GAD-7 8); Mood Disorder Questionnaire negative; no thoughts of suicide or self-harm | active | confirmed | F32.1 | S — Synthetic modern diagnosis; the historical and retrospective mental-health accounts are not coded. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Pelvic pain score (0 to 10), pain with intercourse and bowel movements, and missed working days | Every visit | Completed today | Ache on most days, less than before; no bowel pain this week; no missed work since the first visit |
| Self-management | Bleeding pattern on continuous suppression | Every visit | Completed today | No bleeding in nine days |
| Medication safety | Combined pill: adherence, side effects, and reasons to stop estrogen (migraine with aura, high blood pressure, clot symptoms, smoking) | Every visit, with blood pressure | Completed today | Taken daily; one day of nausea; blood pressure 110/70; no migraine with aura, clot symptoms or smoking |
| Medication safety | Naproxen: days used each month, and stomach or kidney symptoms | Every visit | Completed today | Naproxen on four days, with food; no stomach pain |
| Medication safety | No opioid, benzodiazepine, or sleep-medicine accumulation; prescription monitoring program | At the start, then every visit while pain is active | Completed today | No opioid or sedative since the first visit; diphenhydramine stopped; the prescription monitoring program was checked at the first visit |
| Imaging | Transvaginal ultrasound: endometrioma size and deep disease | At diagnosis; repeat at about four months on medical treatment, then yearly or if symptoms change | Completed today | 3.4 by 2.9 cm typical left endometrioma; no deep nodules; no adenomyosis |
| Laboratory | CA-125 | Not used to diagnose endometriosis | Not indicated | The ESHRE guideline advises against CA-125 for diagnosis; the ultrasound features are typical of an endometrioma |
| Laboratory | Ovarian reserve (anti-Mullerian hormone) | For fertility counseling and before any ovarian surgery | Completed today | 2.6 ng/mL, typical for her age; antral follicles 9 right and 6 left |
| Examination | Pelvic examination | At diagnosis, and when pain persists or changes | Completed today | Left adnexal and uterosacral tenderness; no rectovaginal nodule |
| Referral | Surgical evaluation (laparoscopic excision) | If pain does not respond to medical treatment, the cyst grows, or imaging is atypical | Completed today | Discussed by Dr. Okoye; not needed now; kept in reserve |
| Self-management | Pregnancy intention and fertility plan | Every visit | Completed today | Wants a pregnancy in about a year; the fertility plan agreed today |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Up to date | PHQ-9 12 nine days ago; next in about four weeks |
| Survey | Anxiety measure (GAD-7) | At diagnosis and with each depression measure | Up to date | GAD-7 8 nine days ago |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; leftover medicines returned to a pharmacy |
| Self-management | Cognitive behavioral therapy engagement | Weekly for the first month, then every two weeks | Completed today | First session done |
| Self-management | Sleep without sedatives | Every visit | Completed today | Regular bedtime; no diphenhydramine |
Goal progress:
Guideline basis: Practice Bulletin No. 114: Management of Endometriosis (2010); ESHRE guideline: endometriosis (2022); Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218 (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Behavioral health weekly. Preventive visit in about eight weeks. Endometriosis review in about three months with the pain score, PHQ-9 and GAD-7, and a repeat ultrasound at about four months. Next scheduled visit 1956-08-17: periodic adult preventive visit with pregnancy planning. [S]